Clinical trials: Normal Eyes
Sjögren's Syndrome, Xerostomia
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients
Chronic inflammation that comprises the exocrine glands' function leads to xerophthalmia and xerostomia in Sjögren's syndrome. The oral consequences range widely and they are related to decreased salivary output.
- Trial name
- NCT00873496
- Testing
- Hydroxychloroquine
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Ege University
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
TNF-receptor Associated Periodic Syndromes (TRAPS)
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
- Trial name
- NCT01242813
- Testing
- ACZ885
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Retinoblastoma
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active de novo or residual or…
- Trial name
- STEP-RB (NCT04428879)
- Testing
- Topotecan Episcleral Plaque
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- The Hospital for Sick Children
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Neuroblastoma, Relapsed Neuroblastoma
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma
- Trial name
- GPC2 (NCT05650749)
- Testing
- GPC2 CAR T cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stephan Grupp MD PhD
Behçet's Disease
Behçet's Disease and Eosinophil Cationic Protein
Eosinophil cationic protein (ECP) is a matrix protein of eosinophils and has been reported to reflect eosinophil activity. Few studies have examined the role of eosinophils in the pathogenesis of Behçet's disease.
- Trial name
- NCT01584778
- Testing
- eosinophil cationic protein
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Cukurova University
Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas
Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-Intron), used to treat brain tumors in a pediatric population.
- Trial name
- NCT02343224
- Testing
- Pegylated interferon alpha-2b
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Macular Pigmentation, Skin Pigment
Macular Pigment Measurements in Eye & Other Tissues
The purpose of this study is to understand the role of nutrition and its effects on the eye and other tissues. The investigators propose to study this by validating and correlating various non-invasive measurement methods of…
- Trial name
- NCT03022773
- Testing
- Carotenoid measurements
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Utah
Neuroblastoma, Opsoclonus-myoclonus
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus.
- Trial name
- NCT00202930
- Testing
- anti-CD20 (Rituximab)
- Volunteers
- 4 people
- Sponsor
- Jean M. Tersak, M.D.
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
- Trial name
- NCT01231919
- Testing
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 25 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Retinoblastoma, Retinal Neoplasm
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain.
- Trial name
- NCT00186888
- Testing
- Enucleation, Vincristine, Carboplatin, Focal Therapies
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- St. Jude Children's Research Hospital
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Hereditary Retinoblastoma
MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)
The purpose of this study is to assess the benefit of MR screening for asymptomatic head \& neck (or CNS) second primary cancers occurring in hereditary retinoblastoma patients previously treated by external beam radiation…
- Trial name
- DepiSCARRH (NCT03026998)
- Testing
- MRI
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Institut Curie
Thalassemia, Sickle Cell Disease
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic blood and marrow transplantation remains the only viable cure for children who suffer from many serious non-malignant hematological diseases. Transplantation, however, carries a high risk of fatal complications.
- Conditions
- Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome
- Trial name
- NCT01319851
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
The DOLF Ocular Changes after Ivermectin study will investigate the kinetics of O. volvulus microfilaria (Mf) in the eye following treatment with ivermectin.
- Trial name
- NCT03517462
- Testing
- Ivermectin 3Mg Tab
- Where
- Ghana
- Volunteers
- 231 people
- Sponsor
- Washington University School of Medicine
Retinoblastoma
CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma
- Trial name
- NCT02319486
- Testing
- carboplatin periocular injection, CEV chemotherapy
- Volunteers
- 26 people
- Sponsor
- Sun Yat-sen University
Retinoblastoma
Carboplatin Plus Vincristine in Treating Children With Retinoblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002794
- Testing
- carboplatin, vincristine sulfate
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals